0000000000930035

AUTHOR

R Sacco

showing 18 related works from this author

Measurement of the radiative K-e3 branching ratio

2005

We present a measurement of the relative branching ratio of the decay KL -> pi e nu gamma (Ke3gamma) with respect to KL-> pi e nu (gamma) (Ke3+Ke3gamma) decay. The result is based on observation of 19 000 Ke3gamma and 5.6 x 10^6 Ke3 decays. The value of the branching ratio is Br(Ke3gamma, Egamma^*>30 MeV,theta(e,gamma)^*>20^o)/Br(Ke3)= (0.964+-0.008+0.011-0.009)%. This result agrees with theoretical predictions but is at variance with a recently published result.

Nuclear and High Energy PhysicsChiral perturbation theoryPhotonHadronFOS: Physical scienceskaon decay; NEUTRAL KAON; branching ratio7. Clean energy01 natural sciencesNEUTRAL KAONHigh Energy Physics - ExperimentNuclear physicsmesoni KHigh Energy Physics - Experiment (hep-ex)0103 physical sciencesRadiative transfer[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]radiative kaon decays010306 general physicsmesoni K; decadimenti radiativiPhysics010308 nuclear & particles physicsBranching fractionK13 DECAYSBremsstrahlungkaon decayAmplitudedecadimenti radiativibranching ratioAtomic physicsParticle Physics - Experiment
researchProduct

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

2022

Background & Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Methods Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results One hundred PBC cirrhotics were included, 97…

Liver CirrhosisMaleliver decompensationsafetyHepatologyLiver Cirrhosis Biliarydecision curve analysis; efficacy; liver decompensation; safety; total bilirubin; Albumins; Ascites; Bilirubin; Chenodeoxycholic Acid; Humans; Liver Cirrhosis; Male; Liver Cirrhosis BiliaryBiliaryefficacyAscitesBilirubinChenodeoxycholic Acidtotal bilirubindecision curve analysiSettore MED/12AlbuminsHumansdecision curve analysis
researchProduct

Measurement of Semileptonic B Decays into Orbitally Excited Charmed Mesons

2009

We present a study of B decays into semileptonic final states containing charged and neutral D-1(2420) and D-2*(2460). The analysis is based on a data sample of 208 fb(-1) collected at the Y(4S) resonance with the BABAR detector at the PEP-II asymmetric-energy B factory at SLAC. With a simultaneous fit to four different decay chains, the semileptonic branching fractions are extracted from measurements of the mass difference Delta m = m(D**) - m(D) distribution. Product branching fractions are determined to be B(B+ -> D(1)(0)l(+)nu(l)) x B(D-1(0) -> D*+pi(-)) = (2.97 +/- 0.17 +/- 0.17) x 10(-3), B(B+ -> D-2*l(+)nu(e)) x B(D-2*(0) -> D(*)+pi(-)) = (2.29 +/- 0.23 +/- 0.21) x 10(-3), B(B-0 -> D…

Semileptonic decayParticle physicsMesonBABARHadronAnalytical chemistryGeneral Physics and AstronomyFOS: Physical sciencesB meson01 natural sciencesPARTICLE PHYSICS; PEP2; BABARHigh Energy Physics - ExperimentParticle decayHigh Energy Physics - Experiment (hep-ex)Pion0103 physical sciencesPEP2[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]B meson010306 general physicsB meson; CP violationPhysics010308 nuclear & particles physicsBranching fractionParticle physicsBABAR detectorHEPB-factoryCP violationBaBarPARTICLE PHYSICSFísica de partículesExperimentsPHYSICAL REVIEW LETTERS
researchProduct

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

2011

none 25 no Abstract OBJECTIVES: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics. METHODS: We performed a multicenter retrospective cohort study of patients treated with MTX in MS centers under the Italian national health care system between 1998 and 2008. Demographic, disease, treatment, and follow-up information were collected using hospital records. RESULTS: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%…

Malemedicine.medical_specialtyMyeloidmitoxantrone; acute myelocytic leukemia; multiple sclerosisPopulationmultiple sclerosisStatistics NonparametricmitoxantroneFollow-Up StudieArts and Humanities (miscellaneous)Retrospective StudieInternal medicineMultiple SclerosimedicineHumansmultiple sclerosis leukemia mitoxantroneProspective cohort studyeducationRetrospective StudiesAgedAnalgesicseducation.field_of_studyMitoxantroneCumulative dosebusiness.industryMultiple sclerosisIncidence (epidemiology)leukemiaMyeloid leukemiaRetrospective cohort studymedicine.diseaseConfidence intervalSurgeryLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureItalyCohortSettore MED/26 - NeurologiaAnalgesicFemaleNeurology (clinical)acute myelocytic leukemiaMitoxantronebusinessFollow-Up Studiesmedicine.drugHuman
researchProduct

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

2013

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…

AdultMaleHBsAgmedicine.medical_specialtyHepatitis B virusTime FactorsAnti-HIV Agentsmedicine.disease_causeGastroenterologyAntiviral AgentsGroup Blaw.inventionPolyethylene GlycolsPharmacotherapyHepatitis B ChronicRandomized controlled triallawPegylated interferonInternal medicinemedicineHumansHepatitis B e AntigensHepatitis B virusbusiness.industryGastroenterologyLamivudineInterferon-alphaAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BRecombinant ProteinsTreatment OutcomeLamivudineImmunologyDNA ViralInterferonDrug Therapy CombinationFemaleHepatitis B; Interferonbusinessmedicine.drug
researchProduct

Search for a muonic dark force at BaBar

2016

Many models of physics beyond the Standard Model predict the existence of new Abelian forces with new gauge bosons mediating interactions between "dark sectors" and the Standard Model. We report a search for a dark boson Z' coupling only to the second and third generations of leptons in the reaction e+e- -> mu+mu- Z', Z' -> mu+mu- using 514 fb-1 of data collected by the BABAR experiment. No significant signal is observed for Z' masses in the range 0.212 - 10 GeV. Limits on the coupling parameter g' as low as 7x10^-4 are derived, leading to improvements in the bounds compared to those previously derived from neutrino experiments.

Particle physicsNuclear and High Energy PhysicsPhysics and Astronomy (miscellaneous)Physics beyond the Standard ModelDark matterBaBar experimentFOS: Physical sciences01 natural sciencesPartícules (Matèria)Standard ModelHigh Energy Physics - ExperimentNONuclear physicsHigh Energy Physics - Experiment (hep-ex)High Energy Physics - Phenomenology (hep-ph)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsBosonPhysicsGauge boson010308 nuclear & particles physicshep-exSettore FIS/01 - Fisica SperimentaleHigh Energy Physics::Phenomenologyhep-phHEPHigh Energy Physics - PhenomenologyParticlesDark matter (Astronomy)[PHYS.HPHE]Physics [physics]/High Energy Physics - Phenomenology [hep-ph]BaBarMatèria fosca (Astronomia)NeutrinoLepton
researchProduct

Improved limits on the lepton-flavor violating decays tau(-) -> l(-)l(+)l(-)

2007

A search for the neutrinoless, lepton-flavor violating decay of the tau lepton into three charged leptons has been performed using 376fb-1 of data collected at an e+e- center-of-mass energy around 10.58 GeV with the BABAR detector at the SLAC PEP-II storage rings. In all six decay modes considered, the numbers of events found in data are compatible with the background expectations. Upper limits on the branching fractions are set in the range (4-8)×10-8 at 90% confidence level. © 2007 The American Physical Society.

Particle physicsVIOLATIONMesonElectron–positron annihilationCharged particleGeneral Physics and AstronomyElectron01 natural sciencesNuclear physicsParticle decaySEARCH; LEPTON; FLAVOR; VIOLATION; BABAR; SLACPositronSEARCH0103 physical sciencesFree energyLEPTON010306 general physicsPhysicsVolume fractionMuon010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologyParticle physicsBABAR detectorLepton flavorCharged leptonHEPGermanium compoundBaBarHigh Energy Physics::ExperimentParticle detectorSLACFísica de partículesExperimentsFLAVORLepton
researchProduct

Evaluation of appendicitis risk prediction models in adults with suspected appendicitis.

2019

Background Appendicitis is the most common general surgical emergency worldwide, but its diagnosis remains challenging. The aim of this study was to determine whether existing risk prediction models can reliably identify patients presenting to hospital in the UK with acute right iliac fossa (RIF) pain who are at low risk of appendicitis. Methods A systematic search was completed to identify all existing appendicitis risk prediction models. Models were validated using UK data from an international prospective cohort study that captured consecutive patients aged 16–45 years presenting to hospital with acute RIF in March to June 2017. The main outcome was best achievable model specificity (pro…

AdulthumanosDecision MakingRisk AssessmentNOapendicectomíaapendicitisevaluación de riesgosAppendectomyHumanshospitalGeneralcollaborativeLS7_4right iliac fossa; appendicitis; collaborativeemergency serviceOriginal Articlesadultoright iliac fossaAppendicitisadult; appendectomy; appendicitis; humans; risk assessment; decision making; emergency service; hospitalLower GIOriginal Articleappendicitis prediction models right iliac fossa painEmergency Service Hospitaltoma de decisiónThe British journal of surgery
researchProduct

A measurement of the K-S lifetime

2002

A measurement of the K_S lifetime is presented using data recorded by the NA48 experiment at the CERN-SPS during 1998 and 1999. The K_S lifetime is derived from the ratio of decay time distributions in simultaneous, collinear K_S and K_L beams, giving a result which is approximately independent of the detector acceptance and with reduced systematic errors. The result obtained is tau_S=(0.89598 +- 0.00048 +- 0.00051)x10^(-10) s, where the first error is statistical and the second systematic.

Systematic errorNuclear and High Energy Physics[PHYS.HEXP] Physics [physics]/High Energy Physics - Experiment [hep-ex]NA48 EXPERIMENT; CERN; ELECTRONICS; SYSTEM; DECAYSFOS: Physical sciencesmesoni K; vita media; K meson lifetimek mesons01 natural sciencesDECAYSHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)ELECTRONICS0103 physical sciencesCERN[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]K short010306 general physicsPhysicslifetimeK-meson lifetimeLarge Hadron ColliderNA48 EXPERIMENT010308 nuclear & particles physicsDetectorHigh Energy Physics::PhenomenologyNA48 experimentK-meson lifetime; K shortDecay timePhysics::Accelerator PhysicsHigh Energy Physics::Experimentk mesons; lifetimeParticle Physics - ExperimentSYSTEM
researchProduct

Measurement of the intrinsic electron neutrino component in the T2K neutrino beam with the ND280 detector

2014

The T2K experiment has reported the first observation of the appearance of electron neutrinos in a muon neutrino beam. The main and irreducible background to the appearance signal comes from the presence in the neutrino beam of a small intrinsic component of electron neutrinos originating from muon and kaon decays. In T2K, this component is expected to represent 1.2% of the total neutrino flux. A measurement of this component using the near detector (ND280), located 280 m from the target, is presented. The charged current interactions of electron neutrinos are selected by combining the particle identification capabilities of both the time projection chambers and electromagnetic calorimeters…

Nuclear and High Energy PhysicsParticle physicsPhysics::Instrumentation and DetectorsSolar neutrinoAstrophysics::High Energy Astrophysical PhenomenaFOS: Physical sciences01 natural sciences7. Clean energyHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsNeutrino oscillationPhysics010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyT2K experimentFísicaSolar neutrino problem3. Good healthCosmic neutrino backgroundNeutrino detectorMeasurements of neutrino speedHigh Energy Physics::ExperimentNeutrino
researchProduct

Measurement of the semileptonic branching fraction of the B_{s} meson

2012

We report a measurement of the inclusive semileptonic branching fraction of the B_s meson using data collected with the BaBar detector in the center-of-mass (CM) energy region above the Upsilon(4S) resonance. We use the inclusive yield of phi mesons and the phi yield in association with a high-momentum lepton to perform a simultaneous measurement of the semileptonic branching fraction and the production rate of B_s mesons relative to all B mesons as a function of CM energy. The inclusive semileptonic branching fraction of the B_s meson is determined to be B(B_s to l nu X)=9.5 (+2.5/-2.0)(stat)(+1.1/-1.9)(syst)%, where l indicates the average of e and mu.

Nuclear and High Energy PhysicsParticle physicssemileptonic branching fractionMesonHigh Energy Physics::Latticesemileptonic branching fraction B_s mesonFOS: Physical sciences01 natural sciencesResonance (particle physics)semileptonic Bs-meson decaysHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Mesons (Nuclear physics)B mesonSDG 7 - Affordable and Clean EnergyMesons (Física nuclear)010306 general physicsNuclear Experiment14.40.Nd 13.20.HePhysics/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energy010308 nuclear & particles physicsBranching fractionLeptons (Física nuclear)High Energy Physics::PhenomenologyBABAR detectorbranching fraction measurementHEPPACS: 14.40.Nd 13.20.HeBaBar detector at SLAC; semileptonic Bs-meson decays; branching fraction measurementLeptons (Nuclear physics)Yield (chemistry)BaBarB_s mesonHigh Energy Physics::ExperimentBaBar detector at SLACsemileptonic Bs-meson decayLeptonProduction rate
researchProduct

Measurement of Neutrino Oscillation Parameters from Muon Neutrino Disappearance with an Off-Axis Beam

2013

The T2K Collaboration reports a precision measurement of muon neutrino disappearance with an off-axis neutrino beam with a peak energy of 0.6 GeV. Near detector measurements are used to constrain the neutrino flux and cross section parameters. The Super-Kamiokande far detector, which is 295 km downstream of the neutrino production target, collected data corresponding to 3.01 x 10(20) protons on target. In the absence of neutrino oscillations, 205 +/- 17 (syst) events are expected to be detected while only 58 muon neutrino event candidates are observed. A fit to the neutrino rate and energy spectrum, assuming three neutrino flavors and normal mass hierarchy yields a best-fit mixing angle sin…

Particle physicsPhysics::Instrumentation and DetectorsSolar neutrinoAstrophysics::High Energy Astrophysical PhenomenaGeneral Physics and AstronomyFluxFOS: Physical sciencesddc:500.201 natural sciences7. Clean energyHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Muon neutrino010306 general physicsNeutrino oscillationPhysics010308 nuclear & particles physics4. EducationHigh Energy Physics::PhenomenologyDetectorSolar neutrino problemNeutrino detectorMeasurements of neutrino speedFísica nuclearHigh Energy Physics::ExperimentNeutrino
researchProduct

Search for the decay K-s -> pi(0)e(+)e(-)

2001

Abstract A search for the decay K S →π 0 e + e − has been made using the NA48 detector at the CERN SPS. Using data collected in 1999 during a 40-hour run with a high-intensity KS beam, an upper limit for the branching fraction B (K S →π 0 e + e − ) −7 at 90% confidence level has been obtained.

PhysicsNuclear and High Energy PhysicsParticle physicsLarge Hadron ColliderBranching fractiondecadimentiDetectorpionKaonsCP VIOLATION; KAONKAONK mesonNuclear physicsmesoni Kmesoni K; decadimentiCP violationLimit (mathematics)CP VIOLATIONK meson; pionradiative decaysBeam (structure)Kaons; radiative decays; chiral perturbation theorychiral perturbation theory
researchProduct

Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi-centre prospective audit

2018

Introduction: Some evidence suggests that primary anastomosis following left sided colorectal resection in the emergency setting may be safe in selected patients, and confer favourable outcomes to permanent enterostomy. The aim of this study was to compare the major postoperative complication rate in patients undergoing end stoma vs primary anastomosis following emergency left sided colorectal resection. Methods: A pre-planned analysis of the European Society of Coloproctology 2017 audit. Adult patients (> 16 years) who underwent emergency (unplanned, within 24 h of hospital admission) left sided colonic or rectal resection were included. The primary endpoint was the 30-day major complic…

MaleMedical auditTreatment outcomeanastomotic leak030230 surgery0302 clinical medicinePostoperative ComplicationsProspective StudiesMulti centreemergency surgeryProspective cohort studyColectomyMedical AuditProctectomyProctectomy/adverse effectsProspective auditPrimary anastomosisAnastomosis SurgicalGastroenterologyMiddle Agedsurgical complicationsEuropeTreatment Outcomecolon canceranastomotic leak; colon cancer; emergency surgery; gastrointestinal surgery; rectal cancer; Surgery; surgical complications; surgical outcomes; Gastroenterology030220 oncology & carcinogenesisPostoperative Complications/etiologyFemaleColectomy/adverse effectsEmergency Treatment/adverse effectsAdultmedicine.medical_specialtyAdolescentsurgical outcomesurgical outcomesLeft sidedNO03 medical and health sciencesYoung Adultsurgical complicationmedicineHumansgastrointestinal surgeryrectal cancerEmergency TreatmentColorectal resectionAgedta3126Anastomosis Surgical/methodsbusiness.industryGeneral surgerySurgical StomasSurgical Stomas/statistics & numerical dataSettore MED/18 - Chirurgia GeneraleMultivariate AnalysisSurgerybusiness
researchProduct

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2021

Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the…

Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performanceCancers
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

2021

Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-u…

OncologyMaleSurvivalHepatocellular carcinomaCohort study Hepatocellular carcinoma Prognosis Sorafenib SurvivalSeverity of Illness IndexAntineoplastic Agent0302 clinical medicineProspective StudiesLiver NeoplasmsGastroenterologyMiddle AgedSorafenibPrognosisTreatment OutcomeItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemaleLiver cancerCohort studymedicine.drugCohort studySorafenibCohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; Survivalmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIAAntineoplastic AgentsRisk Assessment03 medical and health sciencesInternal medicinemedicineHumansneoplasmsPrognostic modelsNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAGold standardmedicine.diseasedigestive system diseasesMulticenter studybusiness
researchProduct

The beam and detector for the NA48 neutral kaon CP violation experiment at CERN

2007

The beam and detector, used for the NA48 experiment, devoted to the measurement of Re (ε{lunate}′ / ε{lunate}), and for the NA48/1 experiment on rare KS and neutral hyperon decays, are described. © 2007 Elsevier B.V. All rights reserved.

Nuclear and High Energy PhysicsParticle physicsacceleratoriNA62 experiment01 natural sciencesLIQUID-KRYPTON CALORIMETERDECAYSNOfasci di particelleKaon beamsNuclear physicsDRIFT CHAMBER ELECTRONICSCERNViolazione di CP0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Kaon decaysdetector; CP violation; Kaon decays010306 general physicsInstrumentation07.05.Fb; 13.20.Eb; 29.40.Vj; 29.27.EgPhysicsCalorimeterLarge Hadron ColliderdetectorCRYSTAL010308 nuclear & particles physicsLIQUID-KRYPTON CALORIMETER; DRIFT CHAMBER ELECTRONICS; PROTON TAGGING DETECTOR; PC FARM; TRIGGER; SYSTEM; READOUT; DECAYS; PERFORMANCE; CRYSTALDetectorPC FARMHyperonNA48 experimentDetectorsMagnetic spectrometerPERFORMANCErivelatoriREADOUTkaon decayCalorimeterTriggerCP violationfasci di particelle; acceleratori; CERN; Violazione di CP; rivelatori; kaon decayCP violationHigh Energy Physics::ExperimentParticle Physics - ExperimentPROTON TAGGING DETECTORSYSTEMBeam (structure)
researchProduct